Experiment: 7NXI

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
2	2D 1H-1H NOESY	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
3	2D 1H-1H TOCSY	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
4	3D HNHA	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
5	3D HNHB	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
6	3D 1H-15N TOCSY	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700
7	3D 1H-15N NOESY	20 mM [U-100% 2H] acetic acid, 50 % v/v H2O, 50 % v/v [U-100% 2H] DMSO, 1.7 mM [U-100% 15N] PAF D19S	50% H2O/50% DMSO	0.007 M	4.5	1 atm	298	Bruker AVANCE III 700

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	700

NMR Refinement
Method	Details	Software
simulated annealing		CYANA

NMR Ensemble Information
Conformer Selection Criteria	all calculated structures submitted
Conformers Calculated Total Number	20
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	processing	TopSpin	3.1	Bruker Biospin
2	chemical shift assignment	CcpNmr Analysis	2.4.2	CCPN
3	peak picking	CcpNmr Analysis	2.4.2	CCPN
4	structure calculation	CYANA	2.1	Guntert, Mumenthaler and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.